SCHEMBL3604743

SCHEMBL3604743

Cc1nn(C)c(Oc2ccc(C=O)cc2Cl)c1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TTR P02766 2/20 0.43
ALDH1A1 P00352 4/20 0.39
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.36
ALDH1A3 P47895 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
GPBAR1 Q8TDU6 2/20 0.35
GAA P10253 1/20 0.34
AOX1 Q06278 1/20 0.34
ALDH3A1 P30838 2/20 0.33
CYP2A6 P11509 2/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607854 0.90 SMN1; SMN2 (0.44) SMN1; SMN2CYP1A2CYP2C9CYP2C19TTR
SCHEMBL3609589 0.80 ALDH1A1 (0.39) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3601056 0.77 SMN1; SMN2 (0.40) SMN1; SMN2CYP1A2CYP2C9CYP2C19TTR
SCHEMBL24162679 0.76 SMN1; SMN2 (0.67) SMN1; SMN2CYP1A2CYP2C9CYP2C19TTR
SCHEMBL3605586 0.76 AR (0.52)
SCHEMBL26719555 0.76 SMN1; SMN2 (0.60) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3607752 0.76 SMN1; SMN2 (0.50) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3607758 0.76 SMN1; SMN2 (0.50) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3605188 0.75 CA2 (0.43) ALDH1A1KDM4EMAPTGPBAR1GAA
SCHEMBL3614492 0.74 SMN1; SMN2 (0.57) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R SMN1; SMN2 4515/4885CYP1A2 137/4885CYP2C9 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.